Morphological and histological kidney structure in diabetic rats model treated with ethanol extracts of jengkol fruit peel (Archidendron pauciflorum)

In a long term, diabetes mellitus (DM) leads to nephropathy due to glomerular hyperfiltration. One of the plant used as a diabetic drug by the community in Karangwangi Village, Cianjur Regency, West Java is the fruit peel of jengkol. Therefore, this study aims to determine the effect of the ethanolic extract of Jengkol fruit peel (EEJFP) toward the morphological and histological structure on the kidney of the diabetic rat model. The method adopted was the Randomized Design (CRD) with 6 treatments namely NC (Carboxyl Methyl Cellulose (CMC) 0.5%), PC (CMC 0.5%), Pb (Glibenclamide 5 mg/kg BW), P1, P2, and P3 (EEJFP 385; 770; and 1,540 mg/kg BW) with 4 replications for 14 consecutive days. Furthermore, the induction of diabetes with streptozotocin dose of 60 mg/Kg BW was performed intravenously in experimental animals except for the NC group. The parameters observed include relative weight, morphological, and histological structure of kidney which include glomerular diameter, Bowman space distance, and percentage of proximal tubular cell necrosis. The non-parametric and parametric data were tested by Kruskal Wallis and ANOVA test as well as Duncan's follow-up test, respectively. The results showed that there was no significant difference in the morphological structure of the kidney between treatment groups. Furthermore, the relative weights of kidney in the PC, Pb, P1, and P3 groups were larger and significantly different compared to NC and P2 also, the histological structure showed that the glomerular diameter (65.43 ± 0.7 m), Bowman space distance (4.19 ± 1.7 µm), and the percentage of proximal tubular cell necrosis (24.6 ± 5.5%) at P2 were not significantly different from NC. Based on this results, it was concluded that EEJFP has no effect on the kidney’s morphological structure, however, it decreases its relative weight and repair the kidney’s histological damage of the diabetic rat model with the optimum dose of 770 mg/kg BW.

Download Full-text

Acute solvent exposure induced activation of cytochrome P4502E1 causes proximal tubular cell necrosis by oxidative stress

Toxicology in Vitro ◽

10.1016/s0887-2333(03)00021-3 ◽

2003 ◽

Vol 17 (3) ◽

pp. 335-341 ◽

Cited By ~ 24

Author(s):

Saeed S. Al-Ghamdi ◽

Martin J. Raftery ◽

Muhammad M. Yaqoob

Keyword(s):

Oxidative Stress ◽

Proximal Tubular Cell ◽

Tubular Cell ◽

Cell Necrosis ◽

Solvent Exposure ◽

Cytochrome P4502e1 ◽

Proximal Tubular

Download Full-text

Role of Renal Cysteine Conjugate β-Lyase in the Mechanism of Compound A Nephrotoxicity in Rats

Anesthesiology ◽

10.1097/00000542-199701000-00020 ◽

1997 ◽

Vol 86 (1) ◽

pp. 160-171 ◽

Cited By ~ 66

Author(s):

Evan D. Kharasch ◽

David Thorning ◽

Kyle Garton ◽

Douglas C. Hankins ◽

Cormac G. Kilty

Keyword(s):

Biochemical Markers ◽

Urine Volume ◽

Proximal Tubular Cell ◽

Tubular Cell ◽

Aminooxyacetic Acid ◽

Cell Necrosis ◽

Urine Excretion ◽

Compound A ◽

Renal Uptake ◽

Proximal Tubular

Background The sevoflurane degradation product compound A is nephrotoxic in rats, in which it undergoes extensive metabolism to glutathione and cysteine S-conjugates. The mechanism of compound A nephrotoxicity in rats is unknown. Compound A nephrotoxicity has not been observed in humans. The authors tested the hypothesis that renal uptake of compound A S-conjugates and metabolism by renal cysteine conjugate beta-lyase mediate compound A nephrotoxicity in rats. Methods Compound A (0-0.3 mmol/kg in initial dose-response experiments and 0.2 mmol/kg in subsequent inhibitor experiments) was administered to Fischer 344 rats by intraperitoneal injection. Inhibitor experiments consisted of three groups: inhibitor (control), compound A, or inhibitor plus compound A. The inhibitors were probenecid (0.5 mmol/kg, repeated 10 h later), an inhibitor of renal organic anion transport and S-conjugate uptake; acivicin (10 mg/kg and 5 mg/kg 10 h later), an inhibitor of gamma-glutamyl transferase, an enzyme that cleaves glutathione conjugates to cysteine conjugates; and aminooxyacetic acid (0.5 mmol/kg and 0.25 mmol/kg 10 h later), an inhibitor of renal cysteine conjugate beta-lyase. Urine was collected for 24 h and then the animals were killed. Nephrotoxicity was assessed by light microscopic examination and biochemical markers (serum urea nitrogen and creatinine concentration, urine volume and urine excretion of protein, glucose, and alpha-glutathione-S-transferase [alpha GST], a marker of tubular necrosis). Results Compound A caused dose-related nephrotoxicity, as shown by selective proximal tubular cell necrosis at the corticomedullary junction, diuresis, proteinuria, glucosuria, and increased alpha GST excretion. Probenecid pretreatment significantly (P < 0.05) diminished compound A-induced increases (mean +/- SE) in urine excretion of protein (45.5 +/- 3.8 mg/24 h vs. 25.9 +/- 1.7 mg/24 h), glucose (28.8 +/- 6.2 mg/24 h vs. 10.9 +/- 3.2 mg/24 h), and alpha GST (6.3 +/- 0.8 micrograms/24 h vs. 1.0 +/- 0.2 microgram/24 h) and completely prevented proximal tubular cell necrosis. Aminooxyacetic acid pretreatment significantly diminished compound A-induced increases in urine volume (19.7 +/- 3.5 ml/24 h vs. 9.8 +/- 0.8 ml/24 h), protein excretion (37.2 +/- 2.7 mg/24 h vs. 22.2 +/- 1.8 mg/24 h), and alpha GST excretion (5.8 +/- 1.5 vs. 2.3 micrograms/24 h +/- 0.8 microgram/24 h) but did not significantly alter the histologic pattern of injury. In contrast, acivicin pretreatment increased the compound A-induced histologic and biochemical markers of injury. Compound A-related increases in urine fluoride excretion, reflecting compound A metabolism, were not substantially altered by any of the inhibitor treatments. Conclusions Intraperitoneal compound A administration provides a satisfactory model of nephrotoxicity. Aminooxyacetic acid and probenecid significantly diminished histologic and biochemical evidence of compound A nephrotoxicity, whereas acivicin potentiated toxicity. These results suggest that renal uptake of compound A-glutathione or compound A-cysteine conjugates and cysteine conjugates metabolism by renal beta-lyase mediate, in part, compound A nephrotoxicity in rats.

Download Full-text

Exploration of the Effect and Mechanism of ShenQi Compound in a Spontaneous Diabetic Rat Model

Endocrine Metabolic & Immune Disorders - Drug Targets ◽

10.2174/1871530319666190225113859 ◽

2019 ◽

Vol 19 (5) ◽

pp. 622-631 ◽

Cited By ~ 3

Author(s):

Ya Liu ◽

Jian Kang ◽

Hong Gao ◽

Xiyu Zhang ◽

Jun Chao ◽

...

Keyword(s):

Blood Glucose ◽

Signaling Pathway ◽

Rat Model ◽

Mtor Signaling ◽

Diabetic Rat ◽

Gene Microarray ◽

Mtor Signaling Pathway ◽

Glucose Fluctuation ◽

Blood Glucose Fluctuation ◽

Diabetic Rat Model

Background: Type 2 Diabetes Mellitus (T2DM) is a world-wide metabolic disease with no cure from drugs and treatment. In China, The Traditional Chinese Medicine (TCM) herbal formulations have been used to treat T2DM for centuries. Methods: In this study, we proposed a formula called ShenQi Compound (SQC), which has been used in clinical therapeutics in China for several years. We evaluated the effect of SQC in a spontaneous diabetic rat model (GK rats) by detecting a series of blood indicators and performing histological observations. Meanwhile, the gene microarray and RT-qPCR experiments were used to explore the molecular mechanism of SQC treatment. In addition, western medicine, sitagliptin was employed as a comparison. Results: The results indicated that SQC and sitagliptin could effectively improve the serum lipid (blood Total Cholesterol (TC) and blood Triglycerides (TG)), hormone levels (serum insulin (INS), Glucagon (GC) and Glucagon-Like Peptide-1 (GLP-1)), alleviated the inflammatory response (hypersensitive C-Reactive Protein (hsCRP)), blood glucose fluctuation (Mean Blood Glucose (MBG), standard deviation of blood glucose (SDBG) and Largest Amplitude of plasma Glucose Excursions (LAGE)), pancreatic tissue damage and vascular injury for T2DM. Compared with sitagliptin, SQC achieved a better effect on blood glucose fluctuation (p<0.01). Meanwhile, the gene microarray and RT-qPCR experiments indicated that SQC and sitagliptin may improve the T2DM through affecting the biological functions related to apoptosis and circadian rhythm. Moreover, SQC might be able to influence the mTOR signaling pathway by regulating Pik3r1, Ddit4 expression. Conclusion: All these results indicate that SQC is an effective therapeutic drug on T2DM. Notably, SQC presents an obvious blood glucose fluctuation-preventing ability, which might be derived from the regulation of the mTOR signaling pathway.

Download Full-text